Tech Company Financing Transactions
Earendil Labs Funding Round
Dimension, DST Global and Hillhouse Capital Group participated in a $787 million funding round for Earendil Labs. This venture round was announced on 3/20/2026.
Transaction Overview
Company Name
Announced On
3/20/2026
Transaction Type
Venture Equity
Amount
$787,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programs, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7th Floor, Building 8, Number 1 Courtyard, Zhongguancun East B701
Beijing, 100080
China
Beijing, 100080
China
Phone
Undisclosed
Email Address
Not Recorded
Overview
Earendil Labs is an AI-powered biotechnology company advancing next-generation biologics for patients with autoimmune diseases, cancer, and other areas of significant unmet medical need. By integrating artificial intelligence across the full R&D life cycle, Earendil Labs and its affiliate Helixon Therapeutics have been building a scalable engine to systematically generate and advance high-quality therapeutic programs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jian Peng
Browse more venture capital transactions:
Prev: 3/19/2026: KEWAZO venture capital transaction
Next: 3/20/2026: Flexzo AI venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs